Live In Play

Live In Play®

Updated: 29-Oct-24 08:15 ET

GSK: GlaxoSmithKline enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline (37.88)

Co announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from Chimagen for $300 million upfront. GSK plans to develop and commercialize CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus and lupus nephritis with potential to expand into related autoimmune diseases.
For over a decade, GSK has been a pioneer in the treatment of lupus. This agreement underscores the importance of novel therapeutic approaches to address the heterogeneity of lupus manifestations and the continued burden, particularly in patients who suffer from severe disease and are refractory to current standard of care.